Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Director/PDMR Shareholding

2nd Jan 2009 07:00

RNS Number : 9904K
PuriCore Plc
02 January 2009
 



Directors' and PDMR Dealings

 PuriCore Directors and PDMR Acquire Shares in the Company

MALVERN, PENNSYLVANIA, AND STAFFORD, UK, 2 January 2009 - PuriCore (LSE: PURI), the life sciences company focused on developing and commercialising proprietary, green solutions that safely, effectively, and naturally kill infectious pathogens, today announces that on 31 December 2008 the following Directors and PDMR have purchased shares in the Company, as set out below:

Name

Number of shares purchased

Purchase Price of shares

Total number of shares held

% of issued share capital

Directors

Gregory Bosch, CEO

Michael Sapountzoglou

100,000

94,000

7.50p

7.56p

600,000

230,000

0.28

0.11

PDMR

Andrea Holtzman Drucker

General Counsel, Company Secretary

100,000

7.50p

150,000

0.07

Enquiries:

Ben Brewerton 

Greg Bosch, CEO

Susan Quigley

Darren Weiss, VP, Finance

Financial Dynamics

PuriCore

+44 (0) 20 7831 3113

+1 484 321 2700

About PuriCore

PuriCore plc (LSE: PURI) is a life sciences company focused on developing and commercialising proprietary green solutions that safely, effectively, and naturally kill infectious pathogens. PuriCore targets markets that depend upon controlling contamination, including food safety in retail and foodservice, medical device disinfection, and wound therapy. The Company's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, which is highly effective in killing bacteria, viruses, and fungal spores, simply from water, common salt, and electricity. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of M. tuberculosis, MRSA, E.coli, Norovirus, H5N1 Avian Influenza, HIV, Salmonella, Polio Virus, Helicobater pylori, and Legionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford, UK. 

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release. 

To subscribe to our investor news alerts, visit http://investor.puricore.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSWUGMWPUPRGAG

Related Shares:

RLM.L
FTSE 100 Latest
Value8,275.66
Change0.00